Your browser is no longer supported. Please, upgrade your browser.
Nanobiotix S.A.
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand34.46M Perf Week6.55%
Market Cap507.40M Forward P/E- EPS next Y-2.70 Insider Trans- Shs Float29.26M Perf Month3.19%
Income- PEG- EPS next Q- Inst Own13.98% Short Float0.04% Perf Quarter-4.19%
Sales2.51M P/S201.99 EPS this Y- Inst Trans- Short Ratio3.46 Perf Half Y-22.82%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range12.85 - 21.55 Perf YTD-10.75%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-31.67% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low14.60% ATR0.53
Employees88 Current Ratio- Sales Q/Q52.20% Oper. Margin- RSI (14)51.72 Volatility2.41% 2.60%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.18 Prev Close14.61
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume3.24K Price14.73
Recom1.50 SMA202.86% SMA50-2.25% SMA200-9.40% Volume597 Change0.81%
Jan-06-21Initiated Evercore ISI Outperform
Jul-20-21 04:15PM  
Jul-01-21 06:39AM  
Jun-30-21 04:15PM  
Jun-23-21 03:23PM  
Jun-04-21 09:34AM  
May-12-21 07:54AM  
Mar-05-21 05:51AM  
Jan-25-21 04:00PM  
Jan-15-21 08:00AM  
Jan-08-21 08:00AM  
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. The company develops NanoXray products to help patients receiving radiotherapy by enhancing the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a sterile aqueous suspension of functionalized crystalline hafnium oxide nanoparticles used for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.